


Insilico Medicine



Insilico Medicine

Headquarters: Global presence with offices in Abu Dhabi, Boston, Hong Kong, Montreal, New York and Shanghai

Sector: Healthcare - Biotechnology

Stage & Funding Type: IPO, last valued at \$1.3B+ (May 2025)

Problem: Traditional drug discovery and development process is lengthy, costly with high-failure rate.

Solution: Pharmaceutical Superintelligence – generative AI-driven end-to-end platform for drug discovery, scientific research and sustainability

Market Opportunity: AI-driven drug discovery (AIDD) has the potential to fundamentally disrupt traditional drug discovery and development process by dramatically reducing time, costs, and failure rates.

Traction:

- Rentosertib is one of the most advanced AI-driven drug candidates globally with positive phase 2a results published and has the potential to become the first approved AI-based drug
- Insilico reduced drug discovery timelines from the traditional 2.5–4 years to just 12–18 months, while synthesizing and testing 60–200 molecules per program
- Insilico has nominated 22 preclinical candidates, received IND clearance for 10 molecules

Snapshot of Lead / Notable Investors:

- Warburg Pincus, Qiming Venture Partners, Capital Group, Prosperity7, Value Partners, Lilly Asia Ventures, Sinovation

Team: Alex Zhavoronkov (Founder, CEO and CBO), Alex Aliper (Co-Founder and President), Leah Liu (Head of Capital Markets)

Contact Information: Leah Liu (Head of Capital Markets), IR@insilico.ai

**FUTURE
INVESTMENT
INITIATIVE**
Powered by the FI Institute

EDITION
9TH